Browsing by Author "Ozkan, Tayyar Alp"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    An Independent Validation of 2010 Tumor-Node-Metastasis Classification for Renal Cell Carcinoma: A Multi-center Study by the Urooncology Association of Turkey Renal Cancer-Study Group
    (GALENOS YAYINCILIK, 2017-01-01) Ozkan, Tayyar Alp; Eskicorapci, Saadettin; Yaycioglu, Ozgur; Akdogan, Bulent; Gogus, Cagatay; Dirim, Ayhan; Can, Cavit; Yildirim, Asif; Ozen, Haluk; Turkeri, Levent; Renal, Urooncology Assoc Turkey
    Objective: The American Joint Committee on Cancer tumor-node-metastasis (TNM) classification has been updated by the 7th edition in 2010. The objective of the study was to evaluate cancer-specific survival (CSS) in patients with renal cell carcinoma (RCC) and assess the concordance of 2002 and novel 2010 TNM primary tumor classifications. Materials and Methods: A retrospective analysis of RCC registries from 25 institutions of the Urooncology Association of Turkey Renal CancerStudy Group was performed. Patients with RCC had a radical or partial nephrectomy. The database consisted of 1889 patients. Results: Median follow-up time was 25 months (interquartile range: 11.2-47.8). The 5-year CSS rate for pT1a, pT1b, pT2a, pT2b, pT3a and pT4 tumors were 97\% {[}95\% confidence interval (CI): 0.93-0.99], 94\% (95\% CI: 0.91-0.97), 88\% (95\% CI: 0.81-0.93), 77\% (95\% CI: 0.64-0.86) 74\% (95\% CI: 0.65-0.81) and 66\% (95\% CI: 0.51-0.77), respectively according to the 2010 TNM classification (p<0.001). CSS comparisons between pT1a-pT1b (p=0.022), pT1b-pT2a (p=0.030), pT3a-pT3b (p<0.001) and pT3b-pT4 (p=0.020) were statistically significant. Conversely, pT2a-pT2b (p=0.070) and pT2b-pT3a (p=0.314) were not statistically significant. Multivariable analyses revealed the pT stage in the 2010 TNM classification as an independent prognostic factor for CSS (p for trend=0.002). C-indexes for 2002 and 2010 TNM classifications were 0.8683 and 0.8706, respectively. Conclusion: Subdividing pT2 does not have a CSS advantage. Moving adrenal involvement to pT4 yielded a more accurate prognosis prediction. T stage and LNI are independent prognostic factors for CSS in RCC. Overall, the novel 2010 TNM classification is slightly improved over the former one. However, shown by C-index values, this improvement is not sufficient to state that 2010 TNM outperforms the 2002 TNM.
  • Thumbnail Image
    Item
    Focal Therapy for Prostate Cancer: Current Status of HIFU
    (GALENOS YAYINCILIK, 2015-01-01) Ozkan, Tayyar Alp; Eskicorapci, Saadettin
    First choice treatment options for Prostate Cancer (PCa) are Radical Prostatectomy (RP), brachytherapy and pelvic radiation therapy in current guidelines. The aim of this paper was to review effectiveness and oncological results of high intensity frequency ultrasound treatment (HIFU) in patients with localized PCa. HIFU technology is based on a principle of focused ultrasound (US) waves in an area-sized 3x3x11 mm with a convex ultrasound probe. HIFU ablation was first successfully used in 1995 for 29 pre-radical prostatectomy patients with unilateral tumors (T2-T2b). This treatment option mostly used in Europe in US it has not been approved yet by Food and Drug Administration (FDA) and is used only for clinical trials. HIFU is a relatively new treatment method and 10 years of mid-term results for survival were began to emerge. HIFU biopsy success rates are about 80\%. There need to be more accurate and improved results in order to define it as a new definitive treatment option for prostate cancer. Although it has low success rates, it can be used for all risk groups (low, medium, high), it can be used as a rescue treatment after unsuccessful HIFU treatment, radiotherapy and brachytherapy.